Benzinga · Aug 4, 2026
UBS Maintains Buy on SI-BONE, Raises Price Target to $25
UBS analyst Patrick Wood maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $24 to $25.
SI
NASDAQ · SIBN
SI-BONE, Inc.
Healthcare · Medical - Devices
$18.95
Down-$0.03 (-0.16%)
Updated Aug 14, 2026, 7:47 PM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 816.58M
- P/E ratio
- -33.89
- Dividend yield
- 0.00%
- 52-week range
- $11.48 – $21.89
- Volume
- 246.71K
- Avg. volume
- 529.81K
Price performance
SIBN price history
1M range · 21 trading sessions · Daily adjusted prices
SIBN closed at $18.95 after 21 trading sessions, up 6.94% for the selected period.
- Last close
- $18.95
- Period change
- +6.94%
- Period low
- $16.47
- Period high
- $19.00
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $19.21 | $19.31 | $18.83 | $18.95 | 246.71K |
| Aug 12, 2026 | $18.57 | $19.13 | $18.39 | $19.00 | 329.28K |
| Aug 11, 2026 | $18.675 | $19.23 | $18.675 | $18.80 | 416.04K |
| Aug 10, 2026 | $18.50 | $19.15 | $18.50 | $18.84 | 349.5K |
| Aug 7, 2026 | $18.10 | $18.63 | $18.035 | $18.61 | 297.28K |
| Aug 6, 2026 | $18.04 | $18.20 | $17.65 | $18.14 | 435.02K |
| Aug 5, 2026 | $18.10 | $18.355 | $17.72 | $18.04 | 623.88K |
| Aug 4, 2026 | $17.72 | $19.35 | $17.72 | $18.44 | 1.25M |
| Aug 3, 2026 | $18.07 | $18.93 | $18.07 | $18.45 | 813.89K |
| Jul 31, 2026 | $17.90 | $18.27 | $17.495 | $17.76 | 369.67K |
| Jul 30, 2026 | $18.44 | $18.59 | $17.91 | $17.99 | 476.07K |
| Jul 29, 2026 | $17.92 | $18.65 | $17.80 | $18.44 | 596.65K |
| Jul 28, 2026 | $17.72 | $18.24 | $17.575 | $17.93 | 704.89K |
| Jul 27, 2026 | $16.91 | $17.26 | $16.73 | $17.05 | 620.11K |
| Jul 24, 2026 | $16.36 | $16.87 | $16.36 | $16.62 | 381.07K |
| Jul 23, 2026 | $16.49 | $16.625 | $16.26 | $16.47 | 331.11K |
| Jul 22, 2026 | $17.02 | $17.29 | $16.59 | $16.71 | 408.08K |
| Jul 21, 2026 | $16.89 | $17.33 | $16.81 | $17.04 | 436.9K |
| Jul 20, 2026 | $17.28 | $17.365 | $16.99 | $17.12 | 371.81K |
| Jul 17, 2026 | $17.48 | $17.71 | $16.86 | $17.38 | 403.8K |
| Jul 16, 2026 | $17.55 | $18.17 | $17.135 | $17.72 | 552.9K |
Latest SIBN news
The latest Smart Investors Daily articles mentioning SIBN.
Stock researchCompany · Overview
SIBN research
Overview
Company profile and research snapshot.
Company profile
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $22.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | TD Cowen | Buy | — |
| Aug 4, 2026 | UBS | Buy | — |
| Aug 4, 2026 | Truist Securities | Buy | — |
| Jul 28, 2026 | UBS | Buy | — |
| Jul 16, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 4, 2026
Truist Securities Reiterates Buy on SI-BONE, Raises Price Target to $23
Truist Securities analyst Richard Newitter reiterates SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $21 to $23.
Benzinga · Aug 4, 2026
TD Cowen Maintains Buy on SI-BONE, Raises Price Target to $20
TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $18 to $20.
SeekingAlpha · Aug 4, 2026
SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript
SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call August 3, 2026 4:30 PM EDTCompany ParticipantsSaqib Iqbal - Vice President of Financial Planning & Analysis...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
